The therapeutic concept uses temporal scheduling of NAD+ precursors combined with mitochondrial hormesis induction to restore cellular NAD+ homeostasis while avoiding the adaptive downregulation that occurs with continuous NAD+ augmentation. Rather than constant NAD+ precursor supplementation, this approach leverages the body's natural circadian and ultradian rhythms to synchronize mitochondrial stress signaling with substrate availability, creating coordinated activation of NAD+-dependent sirtuins, PARPs, and metabolic enzymes that drive mitochondrial biogenesis and resilience.[1][2]
The "redox swing" concept recognizes that mitochondria oscillate between reductive (NADH-dominant) and oxidative (NAD+-dominant) states during normal physiological function. Chronic NAD+ supplementation may blunt these natural swings, whereas temporal dosing can amplify the beneficial stress-recovery cycles that drive mitochondrial adaptation.[3]
This approach directly addresses mitochondrial dysfunction in neurodegeneration by combining NAD+ precursor supplementation with circadian-aligned stress recovery cycles.
| Dimension | Specification |
|---|---|
| Modality | Small molecule (NAD+ precursor: NMN, NR, or NRPT) |
| Scheduling | Temporal windows (morning high, evening low/no) |
| Route | Oral (sublingual for NMN) |
| Adjunct | Mild mitochondrial stress (exercise, fasting-mimetic) |
| Indication | Alzheimer's disease, Parkinson's disease, aging-linked cognitive decline |
Patient selection for the redox swing protocol should focus on individuals with measurable NAD+ deficiency:
Blood NAD+ metabolomics: Measure baseline NAD+ and downstream metabolites. Patients with NAD+ levels in the lowest quartile for age may derive the greatest benefit.
Sirtuin activity assays: Peripheral blood mononuclear cell (PBMC) SIRT1 activity provides functional readout of NAD+-dependent enzymatic capacity.
Mitochondrial function markers: Baseline assessment using circulating biomarkers (FGF21, GDF15).
Cognitive baseline: Standardized neuropsychological testing for AD (ADAS-Cog, MMSE) or PD (MoCA, MDS-UPDRS).
| Biomarker | Timing | Target Change |
|---|---|---|
| Plasma NAD+ | Week 2, 4, 8, 12 | 30-50% increase from baseline |
| NAD+/NADH ratio | Week 4, 12 | Normalize to youthful range |
| SIRT1 activity (PBMC) | Week 8, 12 | 20-40% increase |
| Plasma GDF15 | Week 12 | Decreased (improved mitochondrial signaling) |
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 7 | Temporal scheduling of NAD+ is a novel paradigm; continuous supplementation is established |
| Mechanistic Rationale | 8 | NAD+ decline is well-documented; circadian alignment adds mechanistic depth |
| Addresses Root Cause | 7 | Addresses metabolic dysfunction; not disease-specific root cause |
| Delivery Feasibility | 9 | Oral small molecules; established safety profiles |
| Safety Plausibility | 8 | Both NMN and NR have strong safety data; timing reduces risk |
| Combinability | 9 | Highly compatible with exercise, fasting, other metabolic interventions |
| Biomarker Availability | 8 | NAD+ metabolomics, sirtuin activity, mitochondrial function assays |
| De-risking Path | 7 | Preclinical models available; clinical trials of continuous NAD+ ongoing |
| Multi-disease Potential | 9 | High relevance to AD, PD, ALS, aging, metabolic syndrome |
| Patient Impact | 8 | Addresses fundamental aging mechanism; potentially disease-modifying |
Total: 70/100
Morning protocol (within 30 min of waking):
Rationale: Morning administration aligns with circadian NAD+ rise and supports daytime mitochondrial activity and SIRT1-mediated deacetylation of clock genes.
Evening protocol:
Morning protocol:
Evening protocol:
Rationale: Exercise amplifies mitochondrial stress signaling while NAD+ substrate is available, maximizing sirtuin and AMPK activation during recovery.
Personalized scheduling based on biomarker responses:
The redox swing protocol has significant potential for combination with other therapeutic approaches targeting mitochondrial and metabolic pathways:
With SIRT1 Activation + NAD+ Combination Therapy: The redox swing protocol provides temporal coordination while SIRT1 activation provides complementary epigenetic effects. SIRT1-mediated deacetylation of PGC-1α works synergistically with NAD+ elevation to maximize mitochondrial biogenesis.
With exercise: Morning NAD+ dosing combined with aerobic exercise creates amplified mitochondrial stress-response activation. Exercise induces mild mitochondrial stress that, when combined with elevated NAD+ substrate availability, maximally activates SIRT1 and AMPK during the recovery period.
With intermittent fasting: Evening dose reduction during fasting windows enhances autophagy-gymphatic clearance. The natural decline in NAD+ during the fasting state supports cellular stress pathways that drive protein quality control.
With VPS35 Retromer Stabilizer: NAD+ supports endosomal pH and trafficking fidelity through SIRT1-mediated VPS35 deacetylation, complementing retromer stabilization approaches for neurodegenerative disease.
| Phase | Design | Endpoints |
|---|---|---|
| Phase 1 | Crossover, temporal vs. continuous | NAD+ pharmacokinetics, tolerability |
| Phase 2 | Randomized, biomarker-driven | NAD+ metabolites, mitochondrial function, cognition |
| Phase 3 | Adaptive, multi-center | Clinical endpoints in AD/PD |
Multiple studies document the 30-50% decline in brain NAD+ levels with aging and its contribution to neurodegeneration[4:1]. This decline affects three major NAD+-dependent enzyme families: sirtuins (SIRT1-7), poly(ADP-ribose) polymerases (PARPs), and CD38/CD157 ectoenzymes[1:1].
SIRT1, located primarily in the nucleus, deacetylates PGC-1α to drive mitochondrial biogenesis and regulates circadian clock genes[2:1]. SIRT3, resident in mitochondria, deacetylates and activates key antioxidant enzymes including SOD2 and IDH2, protecting neurons from oxidative stress[3:1]. The therapeutic potential of SIRT1 activation is enhanced when combined with adequate NAD+ substrate availability.
Mitochondrial homeostasis requires coordination between mitophagy (selective degradation of damaged mitochondria) and mitochondrial biogenesis (generation of new organelles)[5:1]. The NAD+-SIRT1-PGC-1α axis is central to this coordination.
Several clinical trials have demonstrated safety and biomarker effects of NAD+ precursors. NR (nicotinamide riboside) shows increased NAD+ levels in blood and CSF with daily doses of 250-1000mg with favorable safety profiles. NMN early-phase human trials demonstrate dose-dependent NAD+ elevation.
The circadian regulation of NAD+ metabolism creates therapeutic opportunities[7:1]. NAD+ levels naturally peak in the late morning and decline through the afternoon and evening. Aligning therapeutic dosing with these natural rhythms may enhance efficacy while reducing adaptive downregulation.
| Milestone | Duration | Estimated Cost | Key Activities |
|---|---|---|---|
| Temporal dosing optimization | 3 months | $150,000 | Mouse PK/PD studies comparing continuous vs. temporal NMN dosing schedules |
| Circadian alignment studies | 3 months | $120,000 | Morning vs. evening dosing in aged mouse models; circadian gene expression profiling |
| GLP toxicology (temporal protocol) | 6 months | $400,000 | IND-enabling toxicology with temporal dosing paradigm |
| Biomarker assay development | 3 months | $80,000 | NAD+ metabolomics, sirtuin activity assays for clinical trials |
Phase 1 Total: ~$750,000
| Component | Estimated Cost | Description |
|---|---|---|
| Site setup (3 sites) | $150,000 | Clinical site initiation, IRB approvals, staff training |
| Participant recruitment | $100,000 | 24 participants (8 per arm) for crossover design |
| Study conduct | $300,000 | 12-week treatment periods, PK sampling, safety monitoring |
| Bioanalysis | $75,000 | NAD+ metabolomics, biomarker assays |
| Data management & statistics | $100,000 | Electronic data capture, statistical analysis |
| Regulatory (IND maintenance) | $50,000 | FDA interactions, protocol amendments |
Phase 2a Total: ~$775,000
| Component | Estimated Cost | Description |
|---|---|---|
| Site expansion (10 sites) | $400,000 | Multi-center site initiation |
| Participant enrollment | $500,000 | 150 participants with early AD/PD (50 per arm) |
| Study conduct (18 months) | $1,200,000 | Biomarker-guided dosing, cognitive assessments |
| Advanced biomarker panels | $300,000 | NAD+ metabolomics, mitochondrial function assays, p-tau/NfL |
| MRI imaging | $250,000 | Baseline and longitudinal brain imaging |
| Data management & statistics | $200,000 | Integrated biomarker-clinical database |
| Regulatory strategy | $100,000 | End-of-Phase 2 meeting, breakthrough therapy designation |
Phase 2b Total: ~$2,950,000
| Component | Estimated Cost | Description |
|---|---|---|
| Global site network (30 sites) | $1,500,000 | Site initiation across US/EU |
| Participant enrollment | $2,000,000 | 500 participants with mild cognitive impairment due to AD |
| 24-month treatment period | $4,000,000 | Clinical operations, drug supply, monitoring |
| Clinical endpoints | $500,000 | Cognitive batteries, functional assessments |
| Biomarker substudy | $400,000 | CSF and blood biomarker correlates |
| MRI/PET imaging | $800,000 | Amyloid/tau PET, volumetric MRI |
| Data management | $600,000 | Integrated clinical-imaging-biomarker database |
| Regulatory (NDA filing) | $300,000 | NDA preparation, FDA/EMA interactions |
Phase 3 Total: ~$10,100,000
| Phase | Duration | Cost |
|---|---|---|
| Preclinical | 12 months | $750,000 |
| Phase 1 | 6 months | $775,000 |
| Phase 2 | 18 months | $2,950,000 |
| Phase 3 | 24 months | $10,100,000 |
| Total | 60 months | $14,575,000 |
Page created: 2026-03-12
Last updated: 2026-03-12 16:48 PT
Category: Biomarker-driven / Temporal intervention
Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology. 2021. ↩︎ ↩︎
Imai SI, Guarente L. NAD+ and sirtuins in aging and disease. Trends in Cell Biology. 2014. ↩︎ ↩︎
Vannini N, Campos V, Girotra M, et al. The NAD-Booster Nicotinamide Riboside Potently Stimulates Hematopoiesis through Increased Mitochondrial Clearance. Cell Stem Cell. 2019. ↩︎ ↩︎
Zhu XH, Lu M, Lee BY, et al. NAD+ deficiency is a common denominator in neurodegenerative diseases. Nature Reviews Neurology. 2015. ↩︎ ↩︎
Yoshino J, Baur JA, Imai SI. NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR. Cell Metabolism. 2018. ↩︎ ↩︎
Ronty M, Taverner Y. Mitochondrial hormesis: a new dimension to exercise benefits. Journal of Physiology. 2017. ↩︎
Reinke H, Asher G. Circadian NAD+ metabolism. Nature Reviews Molecular Cell Biology. 2019. ↩︎ ↩︎